Advancements in MRSA treatment: the role of berberine in enhancing antibiotic therapy

BMC Microbiol. 2024 Dec 27;24(1):540. doi: 10.1186/s12866-024-03692-9.

Abstract

Background: Methicillin-resistant Staphylococcus aureus (MRSA) is a significant public health problem. This study investigated the antimicrobial properties and mechanisms of berberine (BBR), a plant alkaloid, against MRSA, evaluating its potential to enhance antibiotic therapy.

Results: Berberine only demonstrated variable but significant inhibitory effects on 50 clinical MRSA strains. When combined with antibiotics, synergistic effects were observed only with amikacin in 6 of the 50 MRSA strains. BBR disrupted MRSA cell wall integrity, leading to leakage of cellular contents. Network pharmacology analysis revealed that BBR targets multiple pathways essential for bacterial survival.

Conclusion: The study confirmed the potent antimicrobial activity of berberine against MRSA and its capability to act synergistically with traditional antibiotics. Berberine's impact on cell wall integrity and bacterial survival pathways highlights its potential as an adjunct therapy in MRSA treatment.

Keywords: Berberine; Cell wall damage; Methicillin-resistant Staphylococcus aureus; Minimum inhibitory concentration; Network pharmacology.

MeSH terms

  • Amikacin / pharmacology
  • Anti-Bacterial Agents* / pharmacology
  • Berberine* / pharmacology
  • Berberine* / therapeutic use
  • Cell Wall / drug effects
  • Drug Synergism*
  • Humans
  • Methicillin-Resistant Staphylococcus aureus* / drug effects
  • Microbial Sensitivity Tests*
  • Staphylococcal Infections* / drug therapy
  • Staphylococcal Infections* / microbiology

Substances

  • Berberine
  • Anti-Bacterial Agents
  • Amikacin